Our Solutions

Administration forms


InnoCore’s injectable bioresorbable solid implants find application as drug delivery depots in various chronic disease areas, such as ophthalmology, oncology and CNS. They can be used for local as well as for systemic drug delivery of small molecules, peptides and proteins for up to 6 months. InnoCore has the disposal of advanced (micro)extrusion technologies allowing effective implant formulation development of the customers active compound with bioresorbable polymers.


The ability to extrude bioresorbable polymers at relatively low temperatures enables InnoCore to add a valuable depot formulation technology to its drug delivery portfolio. These low temperatures are a key to maintain drug integrity and prevent the formation of degradation products, especially when proteins and antibodies are involved.


The use of injectable solid implants based bioresorbable polymers opens opportunities for optimized product performance and life cycle management of generic drugs and therefore adds significant value. Newly developed pharmaceutical actives formulated into a solid injectable controlled release mini-rod can benefit from the versatile technology’s chemistry as well through optimized control over release kinetics and minimization of side effects.


InnoCore’s capabilities in development and manufacturing of implants include:

  • Biodegradable and proven safe polymers
  • Full flexibility in size to be used for commercially available injectors
  • Process maintains drug integrity and prevents formation of degradation products
  • Full control over release profile, zero order kinetics
  • High encapsulation efficiency (>85%)
  • Early phase development, upscaling and GMP manufacturing in house

  • Fully automatic implant cutter developed by Integrated extrusion-cutting process line 

  • Hot melt extrusion process with low temperatures to maintain API stability (PGLA refers to 80-100 degrees and SynBiosys® could do 50-70 degrees)
  • Easy scalable processes
  • Proven concepts available for Goserelin with 1, 3 and 6 months release profiles


Read more about InnoCore’s patented SynBiosys® technology here.

Go back to Administration forms

We use cookies for analyzing visitors behavior.